Peptide Isoelectric Point Modification for Controlled Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current controlled-release polymer-based delivery systems for therapeutic peptides face challenges in achieving uniform release kinetics due to variations in peptide size, charge, and conformation, leading to initial burst releases and adverse side effects, as they primarily focus on manipulating the polymer system rather than the bioactive agent itself.
Innovation Solution
Modifying the isoelectric point of bioactive peptides by altering their charge to optimize their interaction with polymer-based delivery systems, thereby controlling the release characteristics, including initial diffusional and erosional release rates, and encapsulation efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If the polymer-based delivery system is manipulated to suit the requirements of a particular bioactive agent, then the release characteristics can be optimized for that specific agent, but the system complexity increases and cannot accommodate peptides with varying size, charge and conformation uniformly
Solution Approach 1:
Instead of manipulating the polymer delivery system to accommodate different peptides (conventional approach), the invention inverts the approach by modifying the peptide molecules themselves to suit the polymer system. This is achieved through chemical modification of peptide side chains or termini to adjust isoelectric point and charge characteristics, enabling uniform encapsulation and release behavior across diverse peptides without complexing the polymer system
Solution Approach 2:
The invention changes the physical-chemical parameters of the peptide (specifically isoelectric point and charge) through chemical modification. By adjusting these parameters, peptides with varying inherent properties can be tailored to have compatible charge characteristics for the polymer matrix, achieving uniform release kinetics without requiring complex polymer formulations for each peptide type
2Speed
If the initial diffusional release rate is increased to achieve faster therapeutic effect, then the onset of action is improved, but excessive burst release occurs leading to adverse side effects
Solution Approach 1:
The invention applies preliminary action by modifying the peptide charge characteristics before encapsulation. By adjusting the isoelectric point through chemical modification, the peptide-polymer interaction is pre-optimized to control the initial diffusional release phase, preventing excessive burst release while maintaining adequate initial therapeutic effect
Solution Approach 2:
By changing the charge parameter of the peptide through chemical modification, the invention controls the electrostatic interactions with the polymer matrix. This parameter change allows tuning of the release profile to achieve appropriate initial release rates without harmful burst effects
3Productivity
If the polymer system degradation rate is increased to enhance erosional release, then the total drug delivery is improved, but the control over release kinetics during the lag phase is reduced
Solution Approach 1:
The invention enables the peptide to essentially self-regulate its release behavior through its modified charge characteristics. The modified peptides interact with the degrading polymer in a predictable manner, maintaining control over release kinetics during the lag phase while allowing enhanced erosional release to improve total delivery
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for predictable modulation of release profiles, reducing initial burst releases, enhancing encapsulation efficiency, and achieving therapeutically effective peptide concentrations, thereby minimizing adverse effects.
Implementation Method 1
modification of the isoelectric point of a bioactive agent such as a peptide molecule, e.g., alteration of the overall charge of the peptide, can predictably modify the release and/or loading characteristics of polymer-based delivery systems
Data Source
AI summary
Described herein are methods and compositions for modulating the release and/or drug loading characteristics of encapsulated bioactive agents in polymer-based delivery systems via direct modification of the isoelectric point and/or net charge of the bioactive agent.